Indian Journal of Clinical Biochemistry Clinical Biochemistry

Autosomal Dominant Polycystic Kidney Disease: Molecular and Biochemical Approaches to Diagnosis, Prognosis and Monitoring

Shakya, Shailendra, Lohani, Neelam, Datta, Sudip Kumar, Mahajan, Sandeep, Das, Chandan Jyoti, Ahirwar, Ashok, Subbiah, Arunkumar, Rani, Lata, Subramanian, Arulselvi, Bandyopadhyay, Sabyasachi, Sanga, Shamita
Springer Nature · 2026-11-19 · DOI 10.1007/s12291-026-01463-z

Abstract

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disorder and a leading monogenic cause of end-stage renal disease (ESRD), affecting up to 12 million people worldwide. The disease arises from pathogenic variants in PKD1 and PKD2 (and, rarely, GANAB, DNAJB11, ALG9 and IFT140), which cause loss of function of the encoded proteins, polycystin-1 and − 2, dysregulate calcium signalling and cell proliferation, and drive progressive cyst formation. This narrative review is centred on the laboratory evaluation of ADPKD, i.e. the molecular and biochemical approaches used for diagnosis, prognosis and monitoring; pathogenesis and therapeutics are retained only as supporting background. Diagnosis is made clinically and by imaging in most patients, interpreted against age and family history; genetic testing is not mandatory for every patient but is indicated in defined situations (equivocal imaging, absent family history, early-onset or discordant disease, living-related donor evaluation and reproductive planning), consistent with the KDIGO 2025 Clinical Practice Guideline. We critically appraise the genetic architecture of PKD1 and PKD2, interference from the six PKD1 pseudogenes, short-read, MLPA and long-read strategies (including the up to 25% gain in yield reported for long-read sequencing in short-read-unresolved cohorts), variant interpretation, and propose a tiered diagnostic algorithm and laboratory test menu applicable to Indian laboratories. Candidate biomarkers (copeptin, fibroblast growth factor-23, monocyte chemoattractant protein-1, serum bicarbonate, uric acid, urinary proteomic panels, microRNAs and metabolomic signatures) are classified as diagnostic, prognostic, progression or treatment-response markers and evaluated for specimen, assay, confounders and level of validation. Only height-adjusted total kidney volume (Mayo Imaging Classification), eGFR and the genotype-based PROPKD score currently have sufficient validation for clinical use; the remaining biomarkers are investigational. Therapies are summarised briefly according to level of evidence, from the established vasopressin V2 receptor antagonist tolvaptan to investigational agents. Finally, we highlight key knowledge gaps and argue for an integrated genomics, proteomics and computational approach, supported by multicentre validation in India, to enable earlier diagnosis and individualised management of ADPKD.

Read at publisher →